indacaterol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
bronchodilators, phenethylamine derivatives 4183 312753-06-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • QAB149
  • QAB-149
  • QAB 149
  • indacaterol
  • Arcapta Neohaler
  • indacaterol maleate
Indacaterol is a long-acting beta2-adrenergic agonist. The pharmacological effects of beta2-adrenoceptor agonist drugs, including indacaterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3’, 5’-adenosine monophosphate (cyclic monophosphate). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle.
  • Molecular weight: 392.50
  • Formula: C24H28N2O3
  • CLOGP: 2.97
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 81.59
  • ALOGS: -4.69
  • ROTB: 6
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.15 mg Inhal.powder

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 19.40 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.48 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 92.50 hours Lombardo F, Berellini G, Obach RS
BA (Bioavailability) 0.46 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
BA (Bioavailability) 0.43 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.744 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 25.763 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 2.773 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 12.764 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 5.570 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 18.290 % High 1
herg hERG pIC50 4.675 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 10.740 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 28.119 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 5.670 % High 1
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,IKBKB,ITK,JAK2,JAK3,KDR,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 45
kinase-selectivity-class AXL,BRAF,EIF2AK3,EPHB4,GRK2,MAP2K6,MAP3K14,STK33,TEK 9
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 3.420 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 15.031 High 1
mh-clint Mouse hepatocyte intrinsic clearance 66.988 High 1
mppb Mouse plasma protein binding (% unbound) 5.520 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 30.549 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 10.930 % High 1
rat-kpuu-brain Rat brain Kpuu 0.023 % High 1
rh-clint Rat hepatocyte intrinsic clearance 81.283 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 42.350 % High 1
rppb Rat plasma protein binding (% unbound) 6.200 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 146.218 uM High 1

Approvals:

DateAgencyCompanyOrphan
July 1, 2011 FDA NOVARTIS
June 29, 2020 PMDA Novartis Pharma K.K.
Nov. 29, 2009 EMA Novartis Europharm Limited

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bacterial disease carrier 325.48 31.87 61 5228 1805 90621353
Superinfection 294.35 31.87 61 5228 3051 90620107
Bronchial secretion retention 285.24 31.87 61 5228 3554 90619604
Bronchospasm 232.20 31.87 74 5215 20635 90602523
Scoliosis 206.87 31.87 56 5233 8851 90614307
Eosinophilia 175.24 31.87 65 5224 28468 90594690
Atelectasis 169.94 31.87 61 5228 24348 90598810
Hyper IgE syndrome 157.24 31.87 27 5262 478 90622680
Sleep disorder due to a general medical condition 156.69 31.87 68 5221 44670 90578488
Aggression 150.09 31.87 57 5232 26611 90596547
Rib fracture 146.97 31.87 56 5233 26379 90596779
Sinus operation 145.53 31.87 34 5255 2957 90620201
Nonspecific reaction 142.33 31.87 33 5256 2776 90620382
Asthma 130.73 31.87 110 5179 242050 90381108
Restrictive pulmonary disease 126.34 31.87 29 5260 2333 90620825
Dyspnoea 111.62 31.87 190 5099 880765 89742393
Polycystic ovaries 101.21 31.87 29 5260 5625 90617533
Treatment noncompliance 99.26 31.87 52 5237 51675 90571483
Illness 94.29 31.87 59 5230 81910 90541248
Wheezing 92.60 31.87 90 5199 237990 90385168
Heart rate increased 90.70 31.87 65 5224 112837 90510321
Atrial fibrillation 87.41 31.87 68 5221 133543 90489615
Dyslipidaemia 84.63 31.87 29 5260 10078 90613080
Chronic obstructive pulmonary disease 82.04 31.87 52 5237 73777 90549381
Palpitations 81.74 31.87 66 5223 136662 90486496
Myalgia 75.25 31.87 70 5219 175055 90448103
Obstructive airways disorder 73.50 31.87 34 5255 25835 90597323
Therapeutic product effect incomplete 72.90 31.87 72 5217 193824 90429334
Impaired quality of life 67.57 31.87 31 5258 23113 90600045
Loss of personal independence in daily activities 67.50 31.87 59 5230 136046 90487112
Abscess 67.00 31.87 29 5260 18862 90604296
Blood pressure increased 64.60 31.87 68 5221 197149 90426009
Blood test abnormal 64.12 31.87 29 5260 20923 90602235
Restless legs syndrome 62.18 31.87 29 5260 22441 90600717
Sinus disorder 61.44 31.87 33 5256 34414 90588744
Coronary artery disease 56.60 31.87 31 5258 33592 90589566
Brain injury 56.30 31.87 20 5269 7718 90615440
Lung neoplasm malignant 54.06 31.87 27 5262 24246 90598912
Sleep apnoea syndrome 52.69 31.87 29 5260 31718 90591440
Skin lesion 48.29 31.87 29 5260 37336 90585822
Paranoia 46.37 31.87 20 5269 12888 90610270
Respiratory failure 44.49 31.87 44 5245 118374 90504784
Eczema 39.13 31.87 29 5260 52841 90570317
Anxiety 39.08 31.87 67 5222 309705 90313453
Pneumonia 38.42 31.87 102 5187 637957 89985201
Disability 33.91 31.87 24 5265 40721 90582437
General physical health deterioration 33.74 31.87 68 5221 355047 90268111
Myocardial infarction 33.68 31.87 36 5253 105936 90517222
Cough 31.94 31.87 68 5221 368894 90254264

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Scleroderma renal crisis 83.48 22.25 16 3147 416 42617756
Rheumatoid nodule 65.80 22.25 19 3144 2976 42615196
Dyspnoea 65.61 22.25 117 3046 442504 42175668
Mesenteric vein thrombosis 39.82 22.25 10 3153 922 42617250
Cardiac failure 36.13 22.25 42 3121 106814 42511358
Intestinal ischaemia 31.77 22.25 15 3148 9373 42608799
Pneumonia 27.67 22.25 81 3082 422068 42196104
Concomitant disease aggravated 26.92 22.25 12 3151 6574 42611598
Rhinovirus infection 23.82 22.25 11 3152 6537 42611635
Bone density decreased 23.29 22.25 8 3155 2198 42615974
SARS-CoV-2 sepsis 22.91 22.25 5 3158 250 42617922

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bacterial disease carrier 300.21 22.45 61 7963 2208 110579067
Bronchial secretion retention 251.92 22.45 61 7963 4963 110576312
Superinfection 243.60 22.45 61 7963 5702 110575573
Bronchospasm 199.51 22.45 77 7947 30162 110551113
Scoliosis 195.80 22.45 56 7968 8677 110572598
Hyper IgE syndrome 143.29 22.45 27 7997 654 110580621
Rib fracture 140.99 22.45 62 7962 33708 110547567
Sinus operation 138.13 22.45 34 7990 2957 110578318
Dyspnoea 136.28 22.45 267 7757 1106605 109474670
Atelectasis 132.88 22.45 61 7963 36651 110544624
Sleep disorder due to a general medical condition 132.53 22.45 68 7956 52044 110529231
Nonspecific reaction 132.19 22.45 33 7991 3041 110578234
Asthma 127.31 22.45 121 7903 250170 110331105
Eosinophilia 122.96 22.45 67 7957 57869 110523406
Restrictive pulmonary disease 110.76 22.45 29 7995 3230 110578045
Polycystic ovaries 99.66 22.45 29 7995 4767 110576508
Aggression 97.44 22.45 58 7966 59152 110522123
Wheezing 92.71 22.45 103 7921 255127 110326148
Atrial fibrillation 89.17 22.45 96 7928 229546 110351729
Illness 84.68 22.45 60 7964 82111 110499164
Chronic obstructive pulmonary disease 79.95 22.45 65 7959 109093 110472182
Palpitations 77.10 22.45 75 7949 159137 110422138
Treatment noncompliance 72.22 22.45 52 7972 72938 110508337
Heart rate increased 71.98 22.45 69 7955 143765 110437510
Scleroderma renal crisis 71.70 22.45 16 8008 907 110580368
Obstructive airways disorder 70.21 22.45 43 7981 46106 110535169
Blood pressure increased 67.12 22.45 88 7936 258285 110322990
Dyslipidaemia 65.60 22.45 29 7995 15936 110565339
Pneumonia 58.47 22.45 167 7857 876547 109704728
Lung neoplasm malignant 57.87 22.45 34 7990 33808 110547467
Myalgia 56.59 22.45 75 7949 222306 110358969
Sinus disorder 56.28 22.45 33 7991 32695 110548580
Loss of personal independence in daily activities 55.18 22.45 61 7963 149959 110431316
Restless legs syndrome 53.65 22.45 29 7995 24597 110556678
Impaired quality of life 53.55 22.45 31 7993 29986 110551289
Therapeutic product effect incomplete 51.66 22.45 72 7952 223733 110357542
Abscess 50.69 22.45 29 7995 27440 110553835
Blood test abnormal 49.65 22.45 29 7995 28525 110552750
Eczema 44.56 22.45 39 7985 72254 110509021
Sleep apnoea syndrome 40.41 22.45 29 7995 40418 110540857
Brain injury 38.37 22.45 19 8005 13457 110567818
General physical health deterioration 37.42 22.45 90 7934 425205 110156070
Cough 36.72 22.45 94 7930 461547 110119728
Skin lesion 36.20 22.45 30 7994 51601 110529674
Disability 35.65 22.45 24 8000 30199 110551076
Cardiac failure 34.12 22.45 54 7970 187572 110393703
Coronary artery disease 33.22 22.45 33 7991 71657 110509618
Paranoia 31.87 22.45 20 8004 22354 110558921
Rheumatoid nodule 31.08 22.45 19 8005 20277 110560998
Anxiety 29.23 22.45 72 7952 345006 110236269
Fall 28.26 22.45 102 7922 603380 109977895
Respiratory failure 27.45 22.45 53 7971 215279 110365996
Off label use 25.26 22.45 44 7980 1500141 109081134
Gastrooesophageal reflux disease 23.80 22.45 45 7979 179931 110401344
SARS-CoV-2 sepsis 22.83 22.45 5 8019 260 110581015

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R03AC18 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Selective beta-2-adrenoreceptor agonists
ATC R03AK14 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC R03AL04 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC R03AL12 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA MoA N0000009922 Adrenergic beta2-Agonists
FDA EPC N0000175779 beta2-Adrenergic Agonist
CHEBI has role CHEBI:35522 β-adrenergic agonist
CHEBI has role CHEBI:35523 bronchodilator agent
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:35554 cardiovascular drug

Related Drugs by ATC class:

R03AC Selective beta-2-adrenoreceptor agonists 17 drugs
bitolterolcarbuterolclenbuterolfenoterolformoterolhexoprenalineisoetarineolodaterolpirbuterolprocaterolreproterolrimiterol show all 17 →
R03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics 13 drugs
beclometasone dipropionatebudesonidecromoglicic acidepinephrinefluticasone furoatefluticasone propionateformoterolisoprenalinemometasone furoatereproterolsalbutamolsalmeterol show all 13 →
R03AL Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids 14 drugs
aclidinium bromidebeclometasone dipropionatebudesonidefenoterolfluticasone furoateformoterolglycopyrronium bromideipratropiummometasone furoateolodaterolsalbutamoltiotropium bromide show all 14 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Asthma indication 195967001 DOID:2841
Prevention of Bronchospasms with Emphysema indication
Prevention of Bronchospasm with Chronic Bronchitis indication
Bronchospasm Prevention with COPD indication
Hypertensive disorder contraindication 38341003 DOID:10763
Hypokalemia contraindication 43339004
Conduction disorder of the heart contraindication 44808001
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Thyrotoxicosis contraindication 90739004 DOID:7997
Prolonged QT interval contraindication 111975006
Seizure disorder contraindication 128613002
Exacerbation of asthma contraindication 281239006
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Congenital long QT syndrome contraindication 442917000
Acutely Deteriorating Chronic Obstructive Pulmonary Disease contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.25 acidic
pKa2 11.06 acidic
pKa3 13.25 acidic
pKa4 9.04 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR AGONIST Ki 7.80 CHEMBL CHEMBL
D(2) dopamine receptor GPCR IC50 4.60 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 6.11 CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 6.25 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 5.70 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 5.75 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 6.45 CHEMBL
D(3) dopamine receptor GPCR Ki 5.98 CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 7.12 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 6.14 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 5.36 CHEMBL
Cytochrome P450 1B1 Enzyme IC50 4.23 CHEMBL
Transmembrane protein 97 Enzyme Ki 6.97 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 7.04 CHEMBL
Serine/arginine-rich splicing factor 6 Nuclear other IC50 4.72 CHEMBL
Beta-2 adrenergic receptor GPCR IC50 8.10 CHEMBL

External reference:

IDSource
4030903 VUID
N0000182968 NUI
D09318 KEGG_DRUG
753498-25-8 SECONDARY_CAS_RN
4030903 VANDF
C1722260 UMLSCUI
CHEBI:68575 CHEBI
CHEMBL1095777 ChEMBL_ID
CHEMBL1789842 ChEMBL_ID
DB05039 DRUGBANK_ID
C510790 MESH_SUPPLEMENTAL_RECORD_UI
7455 IUPHAR_LIGAND_ID
8457 INN_ID
8OR09251MQ UNII
6918554 PUBCHEM_CID
1114325 RXNORM
184350 MMSL
27231 MMSL
30721 MMSL
d07651 MMSL
013439 NDDF
013440 NDDF
702801003 SNOMEDCT_US
702802005 SNOMEDCT_US
703740005 SNOMEDCT_US
8OR09251MQ INXIGHT DRUGS

Pharmaceutical products:

None